Cargando…

Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists

As a currently spotlighted method for cancer treatment, cancer immunotherapy has made a lot of progress in recent years. Among tremendous cancer immunotherapy boosters available nowadays, Toll-like receptor (TLR) agonists were specifically selected, because of their effective activation of innate an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeong, Sehwan, Choi, Yunyoung, Kim, Kyobum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466827/ https://www.ncbi.nlm.nih.gov/pubmed/34575449 http://dx.doi.org/10.3390/pharmaceutics13091374

Ejemplares similares

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

Coacervate-mediated novel pancreatic cancer drug Aleuria Aurantia lectin delivery for augmented anticancer therapy
por: Kim, Sungjun, et al.
Publicado: (2022)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
por: Chakraborty, Samik, et al.
Publicado: (2023)

Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies
por: Farooq, Mariya, et al.
Publicado: (2021)

Toll-Like Receptor-Based Strategies for Cancer Immunotherapy
por: Pahlavanneshan, Saghar, et al.
Publicado: (2021)

Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
por: Hotz, Christian, et al.
Publicado: (2012)

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
por: Andón, Fernando Torres, et al.
Publicado: (2022)

Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets
por: Kim, Sungjun, et al.
Publicado: (2022)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014)

Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates
por: Seong, Jihyun, et al.
Publicado: (2022)

Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods
por: Javaid, Nasir, et al.
Publicado: (2019)

Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma
por: Xun, Yang, et al.
Publicado: (2021)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue
por: Corogeanu, Diana, et al.
Publicado: (2023)

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
por: Bhagchandani, Sachin, et al.
Publicado: (2021)

Age-Dependent Changes of Adipokine and Cytokine Secretion From Rat Adipose Tissue by Endogenous and Exogenous Toll-Like Receptor Agonists
por: Peek, Verena, et al.
Publicado: (2020)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
por: Mett, Vadim, et al.
Publicado: (2021)

Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy
por: Noh, Ji-Yoon, et al.
Publicado: (2020)

The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome
por: Petes, Carlene, et al.
Publicado: (2017)

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
por: Patinote, Cindy, et al.
Publicado: (2020)

Toll-Like Receptor and Cytokine Responses to Infection with Endogenous and Exogenous Koala Retrovirus, and Vaccination as a Control Strategy
por: Kayesh, Mohammad Enamul Hoque, et al.
Publicado: (2021)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

Toll-Like Receptor-4 Modulation for Cancer Immunotherapy
por: Awasthi, Shanjana
Publicado: (2014)

Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
por: Muccioli, Maria, et al.
Publicado: (2014)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity
por: Seya, Tsukasa, et al.
Publicado: (2015)

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy
por: Lende, Stine Sofie Frank, et al.
Publicado: (2022)

Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists
por: Debnath, Sashi, et al.
Publicado: (2022)

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
por: Chan, Michael, et al.
Publicado: (2009)

Toll-like receptor 2 agonists inhibit human fibrocyte differentiation
por: Maharjan, Anu S, et al.
Publicado: (2010)

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
por: Macedo, Amanda B., et al.
Publicado: (2019)

Bibliometric analysis of toll-like receptor agonists associated with cancer therapy
por: Li, Wei, et al.
Publicado: (2022)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
por: Liu, Zhi-Mei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mnhmrnn0uv0rp7222vsbsu2mdr